Analyst Price Targets — LH
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 10, 2026 11:18 am | Ann Hynes | Mizuho Securities | $355.00 | $319.17 | TheFly | Labcorp price target raised to $355 from $320 at Mizuho |
| July 31, 2026 2:49 pm | — | Morgan Stanley | $338.00 | $308.64 | TheFly | Labcorp price target raised to $338 from $308 at Morgan Stanley |
| July 31, 2026 12:54 pm | — | Deutsche Bank | $306.00 | $308.70 | TheFly | Labcorp price target raised to $306 from $276 at Deutsche Bank |
| July 31, 2026 11:19 am | — | Robert W. Baird | $352.00 | $315.53 | TheFly | Labcorp price target raised to $352 from $338 at Baird |
| July 30, 2026 6:50 pm | — | Barclays | $320.00 | $315.82 | TheFly | Labcorp price target raised to $320 from $290 at Barclays |
| May 1, 2026 12:49 pm | Eric Coldwell | Robert W. Baird | $334.00 | $255.97 | TheFly | Labcorp price target raised to $334 from $332 at Baird |
| April 8, 2026 1:14 pm | — | Evercore ISI | $300.00 | $274.72 | TheFly | Labcorp price target raised to $300 from $280 at Evercore ISI |
| February 24, 2026 11:40 am | David Westenberg | Piper Sandler | $300.00 | $285.30 | TheFly | Labcorp price target raised to $300 from $270 at Piper Sandler |
| February 18, 2026 12:48 pm | — | Robert W. Baird | $326.00 | $276.67 | TheFly | Labcorp price target raised to $326 from $313 at Baird |
| January 14, 2026 2:37 pm | — | Robert W. Baird | $313.00 | $259.18 | TheFly | Labcorp price target raised to $313 from $307 at Baird |
Latest News for LH
Enhanced digital experience designed to improve visibility, simplify workflows and support faster decision-making BURLINGTON, N.C., Aug. 31, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory solutions, today announced enhancements to the digital experience of Labcorp Global Trial Connect™, the company's portfolio of clinical trial services, data and technology that…
BURLINGTON, N.C., Aug. 28, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that members of the executive management team will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, Sept.
LH's specialty-testing expansion, strategic partnerships and buybacks support growth, while reimbursement and cost pressures pose risks.
Elecsys® pTau-217 is the first and only FDA-cleared single-biomarker blood test to both rule in and rule out amyloid pathology across specialty and primary care settings Measures phosphorylated Tau 217 (pTau-217), an indicator of amyloid pathology and a hallmark of Alzheimer's disease Intended for individuals 55 and older with signs, symptoms or complaints of cognitive decline BURLINGTON, N.C., Aug. 24, 2026…
Collaboration will support leadership development, practice improvement and innovation across the nation's Community Health Centers BURLINGTON, N.C. and BETHESDA, Md.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.